BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17507879)

  • 1. Relationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophrenia.
    Galińska B; Szulc A; Tarasów E; Kubas B; Dzienis W; Siergiejczyk L; Czernikiewicz A; Walecki J
    Med Sci Monit; 2007 May; 13 Suppl 1():11-6. PubMed ID: 17507879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical and neuropsychological correlates of proton magnetic resonance spectroscopy detected metabolites in brains of first-episode and schizophrenic patients].
    Szulc A; Galińska B; Tarasów E; Walecki J; Dzienis W; Kubas B; Czernikiewicz A
    Psychiatr Pol; 2003; 37(6):977-88. PubMed ID: 14727370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
    Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
    Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.
    Tanaka Y; Obata T; Sassa T; Yoshitome E; Asai Y; Ikehira H; Suhara T; Okubo Y; Nishikawa T
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):365-72. PubMed ID: 16732755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological frontal impairments and negative symptoms in schizophrenia.
    Martino DJ; Bucay D; Butman JT; Allegri RF
    Psychiatry Res; 2007 Aug; 152(2-3):121-8. PubMed ID: 17507100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
    Wood SJ; Berger GE; Lambert M; Conus P; Velakoulis D; Stuart GW; Desmond P; McGorry PD; Pantelis C
    Arch Gen Psychiatry; 2006 Sep; 63(9):969-76. PubMed ID: 16952999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between performance on the Stroop test and N-acetylaspartate in the medial prefrontal cortex in deficit and nondeficit schizophrenia: preliminary results.
    Delamillieure P; Constans JM; Fernandez J; Brazo P; Dollfus S
    Psychiatry Res; 2004 Nov; 132(1):87-9. PubMed ID: 15546706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of auditory event-related potentials and magnetic resonance spectroscopy measures in mild cognitive impairment.
    Li X; Shao X; Wang N; Wang T; Chen G; Zhou H
    Brain Res; 2010 Jul; 1346():204-12. PubMed ID: 20470761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.
    Goto N; Yoshimura R; Kakeda S; Moriya J; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Korogi Y; Nakamura J
    Hum Psychopharmacol; 2009 Dec; 24(8):639-45. PubMed ID: 19946939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fronto-temporal function may distinguish bipolar disorder from schizophrenia.
    Frangou S; Dakhil N; Landau S; Kumari V
    Bipolar Disord; 2006 Feb; 8(1):47-55. PubMed ID: 16411980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
    Szulc A; Galinska B; Tarasow E; Dzienis W; Kubas B; Konarzewska B; Walecki J; Alathiaki AS; Czernikiewicz A
    Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of patients with schizophrenia on the Wisconsin Card Sorting Test (WCST).
    Everett J; Lavoie K; Gagnon JF; Gosselin N
    J Psychiatry Neurosci; 2001 Mar; 26(2):123-30. PubMed ID: 11291529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients].
    Başoğlu C; Cetin M; Oner O; Ebrinç S; Semiz UB; Kandilcioğlu H; Silit E; Kizilkaya E
    Turk Psikiyatri Derg; 2006; 17(2):85-91. PubMed ID: 16755408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study.
    Shirayama Y; Obata T; Matsuzawa D; Nonaka H; Kanazawa Y; Yoshitome E; Ikehira H; Hashimoto K; Iyo M
    Neuroimage; 2010 Feb; 49(3):2783-90. PubMed ID: 19850131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior cingulate gyrus metabolic changes in chronic schizophrenia with generalized cognitive deficits.
    Shimizu E; Hashimoto K; Ochi S; Fukami G; Fujisaki M; Koike K; Okamura N; Ohgake S; Koizumi H; Matsuzawa D; Zhang L; Watanabe H; Nakazato M; Shinoda N; Komatsu N; Morita F; Iyo M
    J Psychiatr Res; 2007; 41(1-2):49-56. PubMed ID: 15993895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proton magnetic resonance spectroscopy of prefrontal lobe and thalamus in schizophrenics: correlation with clinical characteristics].
    Gan JL; Duan HF; Yang JM; Shi ZJ; Zhang DW; Jiang ZK; Gao CY; Wang ZJ
    Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(43):3034-9. PubMed ID: 22333054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia.
    Galińska B; Szulc A; Tarasów E; Kubas B; Dzienis W; Czernikiewicz A; Walecki J
    Med Sci Monit; 2009 Feb; 15(2):CR82-88. PubMed ID: 19179972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia.
    Goldstein RZ; Giovannetti T; Schullery M; Zuffante PA; Lieberman JA; Robinson DG; Barr WB; Bilder RM
    Neuropsychiatry Neuropsychol Behav Neurol; 2002 Jun; 15(2):88-98. PubMed ID: 12050471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Frontal lobe functions in parents of patients with schizophrenia].
    Erol A; Büyükçatalbaş S; Mete L
    Turk Psikiyatri Derg; 2004; 15(2):98-104. PubMed ID: 15208764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.